Binding of deferoxamine to asbestos fibers in vitro and in vivo.
We studied the binding of tritium-labeled deferoxamine, a strong iron chelator, to crocidolite asbestos fibers in vitro and in vivo. In aqueous suspension of asbestos, deferoxamine binding was rapid and strong, suggesting specific binding to iron. For the in vivo experiments, diffusion chambers containing native asbestos fibers or deferoxamine-washed asbestos were implanted in the peritoneal cavities of mice. Five days after parenteral injection of tritiated deferoxamine chambers were removed and the asbestos counted. More than twice as much label (2206 +/- 348 c.p.m./100 mg asbestos) was bound to the native asbestos as compared to the deferoxamine-washed asbestos (1080 +/- 201 c.p.m./100 mg asbestos), suggesting specific binding in vivo. Since deferoxamine can inhibit asbestos toxicity in vitro, these experiments suggest the feasibility of testing whether deferoxamine can prevent asbestos-related disease in vivo.
Weitzman
S A
SA
Department of Medicine, Northwestern University Medical School, Chicago, IL 60611.
Chester
J F
JF
Graceffa
P
P
D000818:Animals; D001194:Asbestos; D001667:Binding, Competitive; D003676:Deferoxamine; D004058:Diffusion; D066298:In Vitro Techniques; D051379:Mice
D001194:Asbestos; D003676:Deferoxamine